Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized‐controlled trial
Summary Background Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. Aim To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia p...
Gespeichert in:
Veröffentlicht in: | Alimentary Pharmacology and Therapeutics 2006-09, Vol.24 (6), p.983-989 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Summary
Background
Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations.
Aim
To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients.
Methods
Newly diagnosed achalasia patients were randomly assigned to receive botulinum toxin 1 month before pneumatic dilatation (botulinum toxin‐pneumatic dilatation group: 27 patients with median age of 38) or to undergo pneumatic dilatation alone (pneumatic dilatation group: 27 patients with median age of 30). Response to therapy was assessed by clinical and objective methods at various intervals.
Results
One‐year remission rate of patients in botulinum toxin‐pneumatic dilatation group was 77% compared with 62% in pneumatic dilatation group (P = 0.1). In pneumatic dilatation group, the oesophageal barium volume significantly (P |
---|---|
ISSN: | 0269-2813 0953-0673 1365-2036 0269-2813 |
DOI: | 10.1111/j.1365-2036.2006.03083.x |